Clinical Trial Update: A Study to Evaluate GEH200520/GEH200521 (18F) Safety and Tolerability When Used for PET Scans in Patients With Solid Tumour Malignancies [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and tolerability of GEH200520/GEH200521 (18F) as a PET imaging tracer in patients with solid tumors; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• GEH200520/GEH200521 (18F) (GEH200520/GEH200521)

Snippet

Sponsor: GE Healthcare | Conditions: Malignant Solid Tumor, Oncology | Phase 1 | Status: RECRUITING